Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

PneumRx inflates its coffers with $11.9mm Series C round; up to $33mm

Executive Summary

PneumRx Inc. (device to treat emphysema) has raised $11.9mm through its Series C round. Since the company filed its initial Form D, which stated it may bring in another $8.6mm before closing the financing, PneumRx has indicated it has up to $33mm in capital commitments. The oversubscribed round was co-led by Forbion Capital Partners, Endeavour Vision, and a strategic corporate partner. Current backers Adams Street Partners, Telegraph Hill Partners, Alta Partners, Spray Venture Partners, Silicon Valley Bank, and Leader Ventures also participated. PneumRx will use the proceeds to advance European sales of the RePneu lung volume reduction coil and to perform a pivotal US trial to support a PMA application. Concurrent with the financing, representatives from Forbion and Endeavour joined PneumRx’s board.

Deal Industry
  • Biotechnology
  • Medical Devices
  • Medical Devices
    • Biomaterials
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies